hotspot -WSS

hotspot

author：explore 2025-09-29 15:24:34 - browse：47

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Clinical trials must include more disabled people

knowledge

WSS

FDA approves Recor Medical high blood pressure device

New definition of a human embryo proposed amid rapid advances

Cancer drug shortages' outsize impact on ovarian cancer patients

Baltimore teen accused of firing into crowd during block party mass shooting

UCSF medical school apologizes for unethical prisoner experiments

Just how powerful is the placebo effect?

entertainment

hotspot

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Extreme heat events are a public health emergency

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The Sacklers, horror, and ‘The Fall of the House of Usher’

Heart attack and stroke risk calculators need revising

Beware the threat of staffing cuts at the CDC

BioMarin wins approval for gene therapy to treat hemophilia A

The Sacklers, horror, and ‘The Fall of the House of Usher’

Medical records are filled with copy

A clever new way to fix Medicaid and graduate medical education

focus

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Senate panel clears PBM, hopsital reforms

Living with Hashimoto's and celiac disease, and med school, too

Free speech concerns arise in wake of journal editor Eisen's firing

ActiGraph execs on goal of drug approvals with digital endpoints

Extreme heat events are a public health emergency

leisure time

knowledge

focus

entertainment